You are here

Article Text

Article menu

See original article:

Download PDFPDF

Correction
Correction
Free

https://doi.org/10.1136/annrheumdis-2013-204577corr1

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Nam JL, Ramiro S, Gaujoux-Viala C, et al. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2014;73:516–28. Figure 2 of this article represented the odds ratios but the legend described risk ratios. The corrected figure 2 is given below.

    Figure 2
    Figure 2

    (A) Risk ratios for the ACR70 responses comparing the use of a biological disease-modifying antirheumatic drug (bDMARD) plus methotrexate (MTX) versus bDMARD monotherapy in patients with rheumatoid arthritis who are MTX-naive. ACR, American College of Rheumatology; *additional study since the 2010 systematic literature review1; † ACR 70 response at 12 months for Breedveld 2006 PREMIER; all other ACR 70 responses are at 6 months. (B) Risk ratios for the ACR70 responses comparing the use of a biological disease-modifying antirheumatic drug (bDMARD) plus methotrexate (MTX) versus bDMARD monotherapy in patients with rheumatoid arthritis who are MTX-incomplete responders. ACR, American College of Rheumatology; *additional study since the 2010 systematic literature review1; ACR 70 responses are at 6 months; †† open-label studies. (C) Risk ratios for the DAS28 remission comparing the use of a biological disease-modifying antirheumatic drug (bDMARD) plus methotrexate (MTX) versus bDMARD monotherapy in patients with rheumatoid arthritis who are MTX-incomplete responders. *Additional study since the 2010 systematic literature review1; † DAS28 remission at 6 months for Kremer 2010 IV Golimumab and Takeuchi EULAR 2013 SURPRISE and ACR 70 at 12 months for Keystone 2010 GO-FORWARD and DOUGADOS EULAR 2012 ACT-RAY; †† open-label study.

    View Abstract

    Linked Articles